PanCanAID – Pancreas Cancer Artificial Intelligence Driven

2 Diagnosis in CT Scan Imaging: A Protocol for a Multicentric

3 Ambispective Diagnostic Study

4 Running Title: Protocol of PanCanAID – Pancreas Cancer AI-Driven Diagnosis

- 5 Seyed Amir Ahmad Safavi-Naini^{1,2}, Armin Behnamnia², Faezeh Khorasanizadeh³, Ali Soroush⁴,
- 6 Farhad Zamani⁵, Faeze Salahshour³, Amir Sadeghi¹, Seyedmahdi Mirtajaddini⁶, Ashkan Zandi⁷,
- 7 Fatemeh Shojaeian⁸, Maryam Saeedi², Azade Ehasni¹, Abdolhamid Chavoshi Khamneh⁴, Zhaleh
- 8 Mohsenifar⁹, Farid Azmoudeh Ardalan¹⁰, Kavous Firouznia³, Shabnam Shahrokh¹, Masoomeh
- 9 Raoufi¹¹, Pooneh Dehghan¹², Pardis Ketabi Moghadam¹, Alireza Mansour-Ghanaei¹³, Parinaz
- 10 Mellatdoust¹⁴, Habib Malekpour¹⁵, Alireza Rasekhi¹⁶, Fariborz Mansour-Ghanaei¹³, Masoudreza
- 11 Sohrabi^{5*}, Fariba Zarei^{16*}, Amir Reza Radmard¹⁷, Hossein Ghanaati^{3*}, Hamid Assadzadeh
- 12 Aghdaei^{1*}, Mohammad Reza Zali¹, Hamid R. Rabiee^{2*}
- 13 1- Gastroenterology and Liver Diseases Research Center, Research Institute for
- 14 Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran,
- 15 Iran
- 16 2- Data Science and Machine Learning (DML) Lab, Department of Computer Engineering,
- 17 Sharif University of Technology, Tehran, Iran
- 18 3- Advanced Diagnostic and Interventional Radiology Research Center (ADIR), Imam Khomeini
- 19 Hospital, Tehran University of Medical Science, Tehran, Iran
- 20 4- Division of Data Driven and Digital Health (D3M), The Charles Bronfman Institute for
- 21 Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- 22 5- Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences,
- 23 Tehran, Iran
- 24 6- Valiasr International Hospital, Tabriz, Iran
- 25 7- School of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta,
- 26 GA, 30332, USA
- 27 8- Sidney Kimmel Comprehensive Cancer Research Center, Johns Hopkins School of Medicine,
- 28 Baltimore, USA
- 29 9- Department of Pathology, Ayatollah Taleghani Educational Hospital, Faculty of Medicine,
- 30 Shahid Beheshti University of Medical Sciences, Tehran, Iran
- 31 10- Pathology and Laboratory Medicine Department, Imam Khomeini Hospital Complex, Tehran
- 32 University of Medical Sciences, Tehran, Iran
- 33 11- Department of Radiology, Imam Hossein Hospital, School of Medicine, Shahid Behesti
- 34 University of Medical Sciences, Tehran, Iran

- 35 12- Imaging Department, Taleghani Hospital; Shahid Behesti University of Medical Sciences,
- 36 Tehran, Iran
- 37 13- Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences,
- 38 Rasht, Iran
- 39 14- Computer Science and Engineering, Dipartimento di Elettronica Informazione e
- 40 Bioingegneria, Politecnico di Milano, Milan, Italy
- 41 15- Department of Adult Gastroenterology and Hepatology, Imam Hossein Hospital, Shahid
- 42 Beheshti University of Medical Sciences, Tehran, Iran
- 43 16- Medical Imaging Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
- 44 17- Department of Radiology, Shariati Hospital, Tehran University of Medical Sciences, Tehran,
- 45 Iran
- 46 * Corresponding to <u>rabie@sharif.edu</u> (HRR) & <u>hamid.assadzadeh@gmail.com</u> (HAA) &
- 47 ghanaati@yahoo.com (HG) & zareifari@sums.ac.ir (FZ) & sohrab_r@yahoo.com (MS) &
- 48 <u>fmansourghanaei@gmail.com</u> (FMG)

49

50 Abstract

51 **Introduction**: Pancreatic cancer is thought to have an extremely dismal prognosis. Most cancer-52 related deaths occur from metastasis rather than the primary tumor, although individuals with 53 tumors smaller than 1 cm in diameter have more than 80% 5-year survival. Thus, the current 54 protocol introduces PanCanAID project which intends to develop several computer-aided-55 diagnosis (CAD) systems to enhance pancreatic cancer diagnosis and management using CT 56 scan imaging.

57 Methods and analysis: Patients with pathologically confirmed pancreatic ductal

adenocarcinoma (PDAC) or pancreatic neuroendocrine tumor (PNET) will be included as

59 pancreatic cancer cases. The controls will be patients without CT evidence of abdominal

60 malignancy. A data bank of contrast-enhanced abdominopelvic CT scans, survival data, and

61 demographics will be collected from ten medical centers in four provinces. Endosonography

62 images and clinical data, if available, will be added to the data bank. Annotation and manual

63 segmentation will be handled by radiologists and confirmed by a second expert radiologist in

64 abdominal imaging. PanCanAID intelligent system is designed to (1) detect abdominopelvic CT

65 scan phase, (2) segment pancreas organ, (3) diagnose pancreatic cancer and its subtype in arterial

66 phase CT scan, (4) diagnose pancreatic cancer and its subtype in non-contrast CT scan, (5) carry

67 out prognosis (TNM stage and survival) based on arterial phase CT scan, (6) and estimate tumor

resectability. A domain adaptation step will be handled to use online data and provide pancreas

69 organ segmentation to reduce the segmentation time. After data collection, a state-of-the-art deep

70 learning algorithm will be developed for each task and benchmarked against rival models.

71 **Conclusion**: PanCanAID is a large-scale, multidisciplinary AI project to assist clinicians in

72 diagnosing and managing pancreas cancer. Here, we present the PanCanAID protocol to assure

the quality and replicability of our models. In our experience, the effort to prepare a detailed

74 protocol facilitates a positive interdisciplinary culture and the preemptive identification of errors

75 before they occur.

76 Keyword: Machine Learning; Pancreatic Neoplasms; Tomography, X-Ray Computed;

77 Endosonography; Artificial Intelligence

78 Introduction

Among all cancer types, pancreatic cancer has an especially dismal prognosis (1). At the time of presentation, only 11% of patients are at an early enough stage to qualify for curative surgery (1-3). In particular, individuals with tumors smaller than 1 cm in diameter showed a relatively favorable average long-term survival rate of 80.4% at five years (4). Therefore, effective early detection of pancreatic cancer is critical for increasing the proportion of individuals who can qualify for treatments that reduce mortality (1). Current methods of pancreatic cancer detection include abdominal computed tomography (CT), endoscopic ultrasonography (EUS), endoscopic

86 retrograde cholangiopancreatography (ERCP), and magnetic resonance imaging (MRI) (5).

87 Fig 1. a) Pancreatic cancer can metastasize to several secondary sites, including the liver, 88 lung, peritoneum, bone, and brain. The most common secondary site is the liver, which is 89 affected in more than half of the cases of metastatic pancreatic cancer. The lung is the 90 second most common site, followed by the peritoneum (6). b) Cancer progression in the 91 pancreas. The tumor is initially confined to the pancreas in stage #1, but it spreads beyond 92 the pancreas to involve nearby lymph nodes in stage #2. By stage #3, the tumor has invaded 93 either the celiac axis or the mesenteric artery. In stage #4, cancer involves other organs 94 outside the pancreas (7). ci) Pancreatic cancer often results from a sequence of genetic 95 mutations that transform normal pancreatic mucosa into an invasive malignancy through 96 precursor lesions. The three most widely recognized precursor lesions are Pancreatic 97 Intraepithelial Neoplasia (PanIN), Intraductal Papillary Mucinous Neoplasm (IPMN), and 98 Mucinous Cystic Neoplasm (MCN). PanIN is the most common precursor lesion for 99 pancreatic ductal adenocarcinoma (PDAC), and genetic abnormalities found in these 100 lesions are common in adjacent PDAC. The histological pattern of PanIN progression also 101 reflects the accumulation of mutations in cancerous tissue. KRAS mutations and shortened 102 telomeres characterize low-grade PanIN lesions. At the same time, high-grade PanIN and 103 PDAC tissues display mutations in p16, p53, CDNK27, and SMAD4, along with a higher 104 frequency of KRAS mutation (8). cii) Image with a green border shows normal acini and 105 normal ducts. The base of acinar cells turns blue due to the abundance of RNA and nuclei, 106 while the cells' apex (or lumenal aspect) appears pink due to the high presence of zymogen 107 proteins that function as digestive enzymes. Intralobular ductule in cross section is obvious. 108 The ductule's lumen contains a granular proteinaceous precipitate that appears pink due 109 to pancreatic juice. The nuclei in images with orange borders are enlarged, 110 hyperchromatic, and show moderate to severe nuclear atypia, with prominent nucleoli 111 representing PanIN. The cytoplasm may be abundant and mucin filled. PanIN, a pre-112 neoplastic lesion of the pancreas, is classified into low-grade and high-grade based on the 113 degree of dysplasia. The epithelial cells display severe nuclear atypia and anaplasia, with

114 loss of polarity and increased mitotic activity. Image with a red border, PDAC is the most 115 common form of pancreatic cancer. On H&E staining, PDAC lesions typically exhibit the 116 following features: desmoplastic reaction, hyperchromatic nuclei with irregular contours 117 and clumped chromatin tumor cells, mitotic figures, and invasion.

118

119 CT scans and EUS are the commonly used imaging examinations for pancreas cancer (9, 10).

120 EUS offers an excellent spatial resolution of the pancreas, and CT scans give information about

121 the tumor and its relationship to surrounding structures. However, EUS is an invasive procedure,

122 and its performance depends on the endoscopist's skill (11, 12). Radiologists also require a

123 considerable amount of training to identify early-stage pancreatic tumors. In a retrospective

124 analysis of pancreatic cancer cases, tumors were detectable in CT images three years before

125 clinical diagnosis (13). Even with expert radiologists, exhaustion and negligence can additionally

126 lead to missed diagnoses (14). These findings suggest an improved review of CT scan exams

127 could increase the proportion of pancreatic cancers diagnosed early.

128 Contrast-enhanced CT scan (CECT) is the preferred technique for pancreas imaging since it

129 characterizes the tumor and surrounding tissue. After the injection of intravenous contrast (IV),

130 the operator takes sequential CT scans at 45 seconds (late arterial phase) and 60 seconds

131 (portovenous phase). Some centers obtain more detailed triple-phase "pancreas protocol"

132 imaging (arterial, venous, and portal) to improve visualization of the tumor and characterization

133 of invasion (15). The effective interpretation of multiple collections of images in different phases

134 requires significant experience and attention.

135 Optimism has steadily grown over the potential of computer-assisted radiology techniques to

136 facilitate early diagnosis and timely management (16, 17). Machine learning (ML) models can

137 explicitly explore hidden patterns in the data and have produced groundbreaking results in

almost all fields of medical imaging (18). Expert radiologists often outperform ML models.

139	However, the cost and limited availability of such expertise impair the early detection of
140	pancreatic cancer (18). ML-driven computerized clinical decision support systems (CDSS) can
141	help less experienced clinicians decrease time-to-diagnosis, increase accuracy, reduce
142	interobserver variability, promote equitable healthcare access, and enhance cost-effectiveness
143	(14, 18).
144	A sizeable multicenter image dataset and interdisciplinary framework are required to develop a
145	generalizable and practical CDSS. Both requirements are especially challenging for pancreatic
146	cancer as the disease is rare, and its management is a winding journey involving many points of
147	care (17, 19). The challenge of obtaining data could explain why few high-performance but data-
148	demanding deep learning models have been published for pancreatic cancer (20). As of 2023, 2
149	out of 13 studies of ML-based pancreatic cancer detection on CT scan imaging had more than
150	300 participants (21), some of which have been summarized in Table 1. Although artificial
151	intelligence (AI)-assisted pancreatic cancer detection is rapidly growing, studies have been
152	hampered by small sample sizes and lack of external validation. Besides, new approaches such as
153	Segment Anything Model (SAM) may improve model performance and facilitate data labeling
154	(20-22).

155 Table 1. Literature of review for diagnostic and prognostic machine learning algorithms

156 for pancreas CT scan imaging (22). Footnote: PDAC: Pancreatic ductal adenocarcinoma; RF:

157 random forest; CNN: convolutional neural network; ML: Machine learning; Acc: Accuracy;

158 AUC: Area under the receiver operating characteristic curve; Internal validation (In); External

159 validation (Ex).

Author, Year	Aim	Algorithm	Data Set	Evaluation
Si et al., 2021	Pancreas cancer	Deep CNN and	319 cases	Ex (AUC): 0.87;
(23)	detection and segmentation and subtype detection	federated learning		Ex (dice score): 83%

Liu et al., 2020 (24)	Pancreas cancer detection	CNN	370 cases and 320 controls (2 External validation sets with 101 cases and 281 cases)	Ex: 98%
Kambakamba	Prediction of post-	ML and	101 cases	In (AUC): 0.72
et al, 2019 (23)	operative listura	analysis		
Mu et al., 2020	Prediction of	CNN	95 cases and	In (AUC): 0.85
(26)	pancreatoenteric fistula		303 controls	Ex (AUC): 0.78
Watson et al., 2021 (27)	Prediction of Response to Neoadjuvant Therapy	CNN and LeNet	81 cases	In (AUC): 0.738
Zhang et al., 2020 (28)	Survival Prediction	Transfer learning; CNN	68 cases and 422 controls and external validation (30 cases)	Ex (Concordance index): 0.65
Kaissis et al, 2020 (29)	Quasi mesenchymal identification of PDAC	RF; Radiomic Feature extraction (Pyradiomics)	207 cases	In (AUC): 0.93
Ma et al., 2020 (30)	pancreatic cancer	CNN	222 cases and 190 controls	In (Acc): 95%

160

ML-guided tools' design and desired outputs must be tailored toward implementation in healthcare systems (14). Thus, the current study describes the protocol for developing several computer-aided diagnoses (CAD) models to facilitate pancreatic cancer management using CT scan images. We sought to develop generalizable CAD systems to aid clinicians with a pancreatic cancer diagnosis (classification, segmentation, cancer subtype detection) and prognosis (cancer resectability, survival, staging) based on pancreas protocol CT scan images from 10 medical centers.

168 Material and methods

169 **Ethical consideration**

- 170 The Institutional Review Board of Research Institute for Gastroenterology and Liver Diseases
- 171 (RIGLD), Shahid Beheshti University of Medical Sciences review board approved this
- ambispective study after consideration of data anonymization and security (code:
- 173 IR.SBMU.RIGLD.REC.1401.043; link:
- 174 <u>https://ethics.research.ac.ir/EthicsProposalViewEn.php?id=323598</u>). This protocol and future
- 175 studies adhere to Helsinki Declaration of 1975, as revised in 2008, which provides ethical
- 176 guidelines for medical research involving human subjects. We have taken necessary measures to
- 177 protect the privacy and confidentiality of all participants and their personal data. Patients will be
- included prospectively from 1 December 2022 until March 2024 and retrospectively from 21
- 179 March 2015 to 23 October 2022. Informed consent will be collected through a phone call from
- 180 the patient or their legal representative, providing a detailed description of the research aim and
- 181 use. However, informed consent collection has been waived for patients collected retrospectively
- 182 or in cases where access to the patient is not possible.

183 Reporting guidelines and checklist

- 184 PanCanAID studies will be conducted adhering to the Standards for Reporting Diagnostic
- 185 Accuracy (2015-STARD and STARD- AI) and Checklist for Artificial Intelligence in Medical
- 186 Imaging (CLAIM) (31-33). The STARD checklist, flow diagram, and CLAIM is presented in S1
- 187 **Table**, **S1 Fig**, and **S2 Table**, respectively.

188 Interdisciplinary Team Building

- 189 Starting in January 2021, a biweekly session was extended, with invitations sent to GI referral
- 190 centers and healthcare providers. The study design involved a team of radiologists,
- 191 gastroenterologists, surgeons, and computer science experts collaborating to develop the study.

192 Together, they discussed the data-gathering process, labeling techniques, and the desired193 machine learning tasks, which resulted in the current study design.

194 Study design

195 This multicentric observational ambispective study will be conducted in ten medical centers in

196 Tehran, Tabriz, and Guilan provinces of Iran: Taleghani Hospital in Tehran (T-H), Emam

197 Khomeini Hospital in Tehran (EK-H), Firozgar Hospital in Tehran (F-H), Emam Hossein

198 Hospital in Tehran (EH-H), Razi Hospital at Guilan province (R-H), Valiasr International

199 Hospital at Tabriz province (V-H), Shariati Hospital in Tehran (S-H), Namazi Hospital at Shiraz

200 Province (N-H), Shahid Faghihi Hosptial at Shiraz (SF-H), Behboud Specialized Clinic for

201 Gastroenterology Diseases (B-C), and the Research Institute of Gastroenterology clinic (RIG-C).

202 Patients will be included prospectively from 1 December 2022 until March 2024 and

203 retrospectively from 21 March 2015 to 23 October 2022. An ethical review board waived

204 gathering informed consent.

205 Patient demographic data will be collected from the electronic hospital information system

206 (HIS). Image data will be obtained from the Picture Archiving and Communication Systems

207 (PACS). EUS images will be obtained from a dedicated system (EndoPACS) at each local

208 hospital system if available. CT scan and EUS images will be gathered in the ".dicom" and

209 ".jpg" series. The medical team conducting the study will call all enrolled patients within two

210 weeks of the enrollment to evaluate the survival and outcome of the cancer. Fig 2 demonstrates

211 the workflow and aims of PanCanAID.

212 Fig 2. Workflow and aims of PanCanAID, a multicentric study to facilitate diagnosis and

213 management of pancreas cancer. Footnote: The black circle represents a contrast-enhanced CT 214 scan, and the half-black circle represents a non-contrast CT scan

215 Patient eligibility, identification, and validation

216 Potential pancreatic cancer cases will be defined accord to using the following criteria: (1) 217 international classification of diseases (ICD) code C25, (2) a histological diagnosis of pancreatic 218 ductal adenocarcinoma (PDAC) OR pancreatic neuroendocrine tumor (PNET) or (3) a radiologic 219 diagnosis of a pancreas mass OR pancreas tumor. Prospective enrollment of potential cases will 220 occur at the time of referral to a radiology center or gastroenterology clinic. 221 Benign and premalignant lesions of the pancreas will be excluded from the case group. Patients 222 without any valid CT scan before the initiation of treatment (chemotherapy or surgery) will be 223 excluded. The treatment initiation will be obtained during a follow-up call or review of patient 224 HIS records. Cases between 20 and 80 years old, with valid CT scan imaging and histologic 225 confirmation of PDAC and PNET from pancreas specimens collected during surgery or FNA 226 biopsy, will be included in the study. The suited CT scan for inclusion of cases and controls is 227 triple phase CT scan or with and without contrast enhanced CT scan. 228 The control group will comprise three subgroups of patients aged 20 to 80 undergoing 229 abdominopelvic CT scan and EUS examination but have no evidence of abdominopelvic 230 malignancy or history of mass resection. The first subgroup will consist of patients without any 231 pancreatic neoplasms. The second subgroup will consist of patients with premalignant lesions, 232 primarily Intraductal papillary mucinous neoplasms (IPMNs), along with pancreatic 233 intraepithelial neoplasia (PanIN) and mucinous cystic neoplasms (MCN) confirmed by pathology 234 report (10). The third subgroup will consist of patients with acute or chronic pancreatitis 235 confirmed by the radiologist. The selection of three subgroups aim to enrich the control group to 236 represent the real-world challenge of diagnosing pancreatic cancer.

237 Phone Interview for Survival and clinical data

238 Our prognostic model aims to predict the 6-month and 1-year survival of patients with pancreatic 239 cancer. To achieve this, the medical team will conduct follow-up calls to both cases and controls, 240 enrolled either retrospectively (over the past year) or prospectively, to collect survival time and 241 relevant risk factors (10). The phone interview form used during these calls is attached in S1 242 **Appendix**. It includes information on the patient's demographics, blood group, symptoms, 243 diagnostic exams, treatments, smoking/alcohol consumption, diabetes/pancreatitis history, family 244 history of cancer/pancreatitis, first symptom-diagnosis interval, and diagnosis-death interval. In 245 addition to the phone interview data, two previously collected datasets from F-Hospital (with a 246 6-year follow-up) and Ekh-Hospital (with a 1-year follow-up) will be used, along with available

247 imaging data retrieved from the PACS system.

248 Sample size

249 Sample size estimation in machine learning projects in medical imaging requires an initial set of 250 annotated data, which in our case, was unavailable (34). Moreover, a reliable method for 251 estimating the sample size of biomedical ML research is unclear, especially with rapidly 252 evolving modeling techniques (34). Figueroa et al. have proposed that between 80 and 560 253 annotated samples in each class are needed to achieve a root mean squared error lower than 0.01 254 (35). Similar studies using CT scan images achieved satisfactory results, with about 250 cases in 255 each class of PDAC and non-PDAC (Table 1). The primary aim of PanCanAID is to collect data 256 from 300 PDAC cases and 300 controls. We will examine the sample size using post hoc curve-257 fitting and the Figueroa method once the first 150 PDAC cases have been collected (75 cases and 258 75 controls) (35).

259 Hospitals and imaging devises

- 260 Data will be collected from ten medical centers in Tehran. The center attributes, including the
- 261 CT scanner model and weekly incidence of pancreatic cancer scans, are described in **Table 2**.
- 262 Different imaging devices and technical variations may result in batch effect, so each patient's
- 263 imaging device and hospital sources will be recorded.

Table 2. Information of ten medical centers that will participate in patient enrollment.

265 Footnote: PDAC: Pancreatic ductal adenocarcinoma; PNET: pancreatic neuroendocrine tumor.

Hospital	GI referral center	Number of beds	CT scan Device	Estimated Workload of Pancreas cancer per week	Previously available data
Ekh-H	Yes	2100	16 Detector Siemens SOMATOM Emotion	15	Yes (100 PNET Cases with CT scan)
EH-H	No	500	16 Detector Siemens Somatom	5	No
Т-Н	Yes	500	16 Decotor Siemenc Somatom	10	No
F-H	Yes	554	16 Detector Siemens Somatom	10	Yes (200 PDAC patients with 2-year follow-up)
R-H	Yes	500	-	7	No
V-H	No	1000	-	3	No
Sh-H	Yes	1000	2-MDCT Siemens Somatorn Volume Zoom, Siemens	15	No
S-H	Yes	850	16-detector Somatom Emotion, Siemens	7	Yes (42 PDAC)
B-C	Yes	-	-	3	No
RIG-C	Yes	-	-	5	Yes (150 PDAC patients)

266 **Online open datasets**

267 We reviewed all previously published open-source pancreatic cancer CT imaging datasets,

268 presented in **Table 3.** Previously segmented images from datasets such as WORD and

- AbdomenCT-1k will segment the pancreas on local images. This segmentation will be revised by
- the first investigator and confirmed by an experienced radiologist.
- 271 **Table 3. Online open dataset for pancreas cancer CT scan imaging.** Footnote: *Data used in
- this publication were generated by the National Cancer Institute Clinical Proteomic Tumor
- 273 Analysis Consortium (CPTAC). Abbreviations: NCI: national cancer institute (of the United
- 274 States of America)

Name	Source	Data	License
AbdomenCT-	GitHub	abdominal CT organ segmentation	Apache-2.0 license
1k (36)	(JunMa11/	dataset with 1000+ CT scans by	
	AbdomenCT-	augmenting the existing single organ	
	1k)	datasets	
WORD (37)	GitHub	abdominal CT organ segmentation	GNU General Public
	(HiLab-	dataset	License v3.0
	git/WORD)		
Vindr (38)	Vindr.ai	Dataset of 1188 scans for phase	One can use the
		recognition in abdominal contrast-	dataset without charge
		enhanced CT	for non-commercial
			research
			purposes only
CPTAC-PDA	The Cancer	The NCI Clinical Proteomic Tumor	TCIA data usage
(39)	Imaging	Analysis Consortium collected CT scan	policy
	Archive	images after pathological confirmation	
	(TCIA)* (40)	of 107 pancreas cancer cases	
Pancreas-CT	The Cancer	The National Institutes of Health	TCIA data usage
(41, 42)	Imaging	Clinical Center performed 82 abdominal	policy
	Archive	contrast-enhanced 3D CT scans in the	
	(TCIA)* (40)	portovenous phase	
Pancreatic-	The Cancer	Breath-hold CT and cone-beam CT	TCIA data usage
CT-CBCT-	Imaging	images with expert manual organ-at-risk	policy
SEG (43, 44)	Archive	segmentations from radiation treatments	
	(TCIA)* (40)	of 40 locally advanced pancreatic	
		cancer patients	
Our future	The Cancer	We plan to provide biphasic CT scans	GNU Affero General
dataset	Imaging	of 500 pancreas cancer cases with	Public License v3.0
(PanCanAID)	Archive or	segmentation on arterial phase and	
	other imaging	patient outcome in 200 cases	
	repositories		

275 Manual segmentation

- 276 We used a panel discussion and Chu et al.'s experience to decide on the segmentation strategy
- 277 (17). Six radiologists will annotate and classify each axial plane of the abdominopelvic CT scan

278 images in arterial phases of CECT using an approaches, an offline 3D slicer 5.0.3 program or an 279 online XNAT server (45). The 3D slicer software will be used on a Windows-based local 280 computer, and annotations will be made using lase pen (XP pen Deco 01 v2). "Brush" and "pen" 281 tools will be used after setting the editable intensity Hounsfield range using the "threshold" tool. 282 Using "threshold" will prevent selecting surrounding elements with different Hounsfield units. In 283 the second approach, and for ease of access, an XNAT application on a Linux server with 200 284 Gb of storage and a two core 8Gb ram (46). 285 A second radiologist with expertise on abdominal imaging will review and confirm the 286 annotations (not blinded to previous segmentations). In case of conflict, the data will be tagged 287 as controversial, and conflicts will be resolved in a dedicated conflict resolution panel with two 288 radiologists. Instruction for radiologists in the Persian language will be available before 289 annotation, and five dedicated cases for educational purposes have been designed to ensure 290 labeling and annotation uniformity.

291 *A*

Active learning for segmentation

292 Providing ground truth annotations for medical images, especially in the case of pancreas 293 images, is very time-consuming and requires limited expert resources. This is especially so for 294 segmentation, where pixel-wise annotation is needed. Hence, we utilize active learning to 295 interact with the annotator. Active learning is a technique in which a machine learning algorithm 296 can improve its accuracy using less labeled training data by selecting the most informative data 297 to learn from. Instead of being given a fixed set of labeled data, an active learner can ask an 298 oracle to label additional instances that are most useful for improving its performance (47). 299 Active learning has been shown to be effective in radiology AI studies (48). We propose an 300 automated system to carefully select the most representative data samples for annotation. We

- 301 also consider the model's uncertainty and approximate error probability on the new data sample
- 302 for the selection. The selected samples are then given to the model for initial annotation. The
- 303 annotated image is given to the radiologist to correct the annotation of the model and then added
- 304 to the set of labeled datasets. After several steps, the newly labeled dataset is given to the model
- 305 for retraining. We continue until the performance improvement stops or a pre-defined proportion
- 306 of the dataset is labeled. The process is summarized in **Fig 3**.

307 Fig 3. Workflow for manual segmentation using active learning approach.

308

309 Mass characteristics

- 310 Radiologists will evaluate tumor characteristics, and this data will be used in the future phases of
- 311 PanCanAID. These characteristics can be used to utilize automated reporting of pancreas mass in
- 312 the future. **Table 4** shows pancreas cancer characteristics.

313 Table 4. The routine report of mass characteristics and source of labeling in PanCanAID.

314 Footnote: CBD: common bile duct; PD: pancreatic duct

Cancer Feature	Classes	Source of labeling
Location	Periampullary-head-body-tail	Radiologist
Morphology	Solid-cystic-mixed	Radiologist
Mass size		Manual segmentation
CBD and PD	Largest diameter in mm in any plane	Radiologist
diameter		
CBD dilation	Yes-no	Radiologist
Stent in situ	Yes-no	Radiologist
TNM stage	Size (T), regional lymph node metastasis	Radiologist- manual
	(N), non-regional metastasis (M)	segmentation (size)
DPCG criteria	Resectable-borderline- irresectable	Radiologist- manual
for classification		segmentation (size)

315

316 **Resectability definition and staging**

317	The National Comprehensive Cancer Network (NCCN) and Dutch Pancreatic Cancer Group
318	(DPCG) guidelines can help physicians in assessing the resectability of tumors (49, 50). This
319	clinical decision is usually challenging for even expert radiologists. Both over- and under-
320	treating can significantly impact a patient's quality of life. We choose the DPCG criteria (Table
321	5) because of its simplicity and lower classification workload. An expert radiologist will classify
322	CT scan images in the arterial phase, and this labeled data will be used to predict the resectability
323	of mass. For TNM staging, a segmented pancreas mass will inform the tumor size (T-stage). A
324	tumor with its longest diameter of less than 2 centimeters in an axial CT scan is defined as T1.
325	Tumors with a diameter of 2-4 centimeters and those wider than 4 centimeters correspond to the
326	T2 and T3 stages, respectively. The T4 stage consists of tumors involving vessels such as the
327	celiac trunk, hepatic artery, and superior mesenteric artery. Radiologists will classify lymph node
328	metastasis (N-stage) as a distant or regional invasion.

329 Table 5. The Dutch Pancreatic Cancer Group (DPCG) criteria to assess the resectability of

330 pancreatic cancer. Footnote: CA: celiac artery; SMA: superior mesenteric artery; CHA:

331 common hepatic artery; SM: superior mesenteric vein; PV: portal vein.

	Resectable	Borderline	Irresectable
Arteries (CA, SMA, CHA)	No contact	< 90 degrees	>90 degrees
Veins (SMV, PV)	<90 degrees (contact)	90-270 degrees (no occlusion)	>270 degrees (or occlusion)
Metastasis	no	no	yes
N-Stage	Locoregional	Locoregional	Extra regional

332

333 Data bank storage and computer processors

334 Data including ".dicom" files of CT scan images, ".jpg" image of EUS, ".csv" files with

335 metadata (including patient characteristics, labels, hospital source, and notes as attached in

336	Supplementary File 1), '	".nrrd" files of 3	D slicer with manua	al segmentations will be stored in	

- three external hard drives with two terabyte storage. Processing will be handled using a pair of
- 338 GTX 1080Ti GPUs. Performance and inference time will be evaluated on both GPU and CPU.

339 CAD systems and tasks

- 340 As Fig 2 depicts, different CAD models will be developed using a databank with specified aims,
 341 including:
- 342 1- Phase detection in abdominopelvic CT scan: classification (non-contrast phase, arterial phase,
- 343 venous phase, portal phase, delay phase)

344 2- Pancreas organ segmentation (pancreas organ segmentation in CECT and non-contrast345 enhanced abdominopelvic CT scan)

346 3- Diagnosis of pancreas cancer in CECT scan: Classification (cancerous vs. non-cancerous),
347 segmentation (pixel perfect pancreas organ and mass), and cancer subtype (PDAC and PNET) in
348 CECT scan images (arterial phase)

4- Diagnosis of pancreas cancer in non-contrast CT scan: Classification (cancerous vs. noncancerous), segmentation (pixel perfect pancreas organ and mass), and cancer subtype
classification (PDAC and PNET) in non-contrast abdominopelvic CT scan images

- 352 5- Prognosis and survival of pancreas cancer in CECT: TNM stage classification including (T:
- 353 size, N: lymph node metastasis, M: distant metastases), and survival (months) in contrast-enhanced
- 354 CT scan images

6- DPCG resectability classification (resectable, borderline, and irresectable) in CECT scan images
(arterial phase)

357 Future Direction: Multimodal approach for pancreas cancer ML tasks: Classification (cancerous

358 vs. non-cancerous), cancer subtype (PDAC and PNET), resectability (resectable vs. irresectable),

and survival (month) using demographics, EUS, and CT scan images

360 Experiments and model development

361

362 conducted to mitigate the variability in data samples due to experimental conditions and
363 measurement device configuration. For CT images, unnecessary slices are removed from the
364 beginning and end of CT image sequences. We design and train a separate classification model

Each input image is contrast-enhanced and denoised for all tasks. Normalization steps are

that detects slices that have the pancreas visible, using the labels already gathered for our data.

366 We consider slices with a minimum amount of detected pancreas area as positive and otherwise

367 as negative. This filtering allows our models to be guided by useful cues and removes the

368 computational cost of processing extra slices.

Fig 4. shows a brief overview of the model development workflow. The tasks are solved

according to the following procedure:

371 Fig 4. A brief overview of PanCanAID model development workflow.

372 1- A multi-instance learning approach is deployed to find substantial slices of data and make an

initial detection of cancer. The features extracted in this step are also used for detecting and

374 segmenting cancerous tissue in the following steps.

375 2- To extend our dataset, we conduct data augmentation. We use the variations between data 376 samples to generate novel data. We train a spatial and an intensity registration network. 377 Registration is a method to match images with the same structure but is distorted and hence not 378 pixel-by-pixel matched (51). It finds a transformation that can map corresponding pixels to each 379 other. We sample from the detected intensity and spatial maps learned from these models 380 throughout the dataset and combine them to create new maps to generate new data. 381 3- A segmentation of the pancreas alongside any suspicious tissue mass is carried out in the 382 CECT image. Due to the lack of labeled data and the cost of manual segmentation, we follow a 383 domain adaptation approach. Domain adaptation has been extensively used in medical data and 384 signals (52), especially in CT images (53) It is used when a model is supposed to be adapted to an 385 unlabeled external domain with the help of the labeled internal dataset. We train a model on 386 public datasets with segmentation labels and adapt the trained model to our dataset. We deploy 387 different reconstruction methods to utilize the unlabeled data in our dataset. Reconstruction is 388 mainly used to force latent features to contain as much information as possible to recreate the 389 input data patterns (54). We gradually add labeled data and update the model according to an 390 active learning framework to carry out the segmentation more accurately.

391 4- The cancer classification task uses segmentation from the original and reconstructed images.
392 The delta image, the original image, and the features extracted in step 1 are processed through
393 another Convolutional Network to detect cancer.

5- Upon cancer detection, we perform an additional classification task (PDAC or PNET) by
processing a neighbor of the segmented mass in relation to the whole image. Local features are
obtained by processing the area around the pancreas as well as the pancreas itself. Global
features are computed based on the global attention of the whole image, considering the

398	relationship between all regions in the image, providing a global representation of the structure
399	of the abdominal CT image (55). We use local features around the segmented area and their
400	relationship along with the global features of the entire image to model both the local
401	information and the significance of this information relative to the global structure of the
402	abdominal area. Local features
403	6- For the resectability classification task, we follow an approach similar to detecting the cancer
404	type. We estimate the chance of successful tumor resection based on local-global feature
405	extraction.
406	7- Segmentation estimation for plain non-contrast CT images is done by matching them to the
407	label assigned to their corresponding CE-CT images. As we have segmentation maps for CE-CT
408	images, we temporally align CT slices of patients with their CE-CT image to use the CE-CT
409	labels as ground truth annotation for the plain CT images. The rest of the procedure is similar to
410	the one for CE-CT images. Other tasks performed on the basic CT images are done similarly, as
411	the true values of cancer labels, resectability, and prognosis results are the same for CE and plain
412	CT images.
413	8- For prognosis, we model survival time as a conditioned normal variable, with mean and
414	variance predicted by a 3D-CNN applied on the combination of the segmentation and original
415	image. The mean head estimates the average survival time, and the (log) variance head estimates
416	the uncertainty of the prediction. We infer mean and variance by maximizing the likelihood of
417	the data.

418 Batch effect removal

We designed a multi-level multi-site batch normalization (MMBN) architecture to remove thebatch effect. We aim to remove batch effect at both the data- and feature-level.

421 Data-level batch effect removal

To remove the effect of different measurement devices, we normalize the intensity and contrast
of the CT images. We also apply affine normalization to remove geometrical biases caused by
the experimental conditions.

425 Feature-level batch effect removal

426 Only some of the variations in the data can be detected by low-level analysis of raw input 427 images. We utilize our multi-site dataset to remove the feature-level batch effect that occurs in 428 higher data abstractions. We deploy a Multi-Site Batch Normalization Layer (MSBNL) that 429 consists of a batch normalization layer for each site in our dataset. The data sample is normalized 430 according to the normalization parameters of its site. For a target site, we first estimate the mean 431 and variance of the samples. Then, for each target-site sample, we pass it to each site-specific 432 batch normalization layer and aggregate them using the weights defined as the KL divergence of 433 the distribution of target site data and the corresponding source site data. To lessen the 434 computational complexity, we assume a normal distribution for the data in each site. More 435 concretely, assume site statistics (mean and variance) estimates from batch normalization parameters are (μ_i, σ_i^2) for each site-specific batch normalization layer and (μ_t, σ_t^2) are the 436 437 statistics of the target site. The weight of each layer for a sample from a target sample is 438 calculated according to Equations 1 and 2:

439 Equation 1:
$$\hat{w}_i = \log \frac{\sigma_i}{\sigma_t} + \frac{1}{2\sigma_i^2} (\sigma_t^2 + (\mu_t - \mu_i)^2) - \frac{1}{2}$$

440 Equation 2:
$$w_i = \frac{\hat{w}_i}{\sum_{j=1}^n \hat{w}_j}$$

441

442 If we don't have enough data from the target site, we also add the likelihood of the target data

443 according to the distribution of each site using Equation 3:

444 Equation 3:
$$\tilde{w}_i = \frac{1}{\sqrt{2\pi\sigma_i^2}} \exp\left[-\frac{1}{2\sigma_i^2}(x_t - \mu_i)^2\right]$$

Where x_t , is a feature of the sample from the target data, u_i and σ_t are expected value and variance of the feature for each domain according to the batch normalization layer, and $\hat{w} = \hat{w} + \hat{w}$ which means that we add computed \hat{w} parameters to \tilde{w} to account for a small amount of data in the target domain.

449 **Evaluation metrics and proposed model**

450 The model performance will be tested in internal validation (test set) and external validation 451 (from external hospital). For segmentation, we use IOU (intersection over union) to evaluate the 452 proportion of detected mass. We also measure pixel-wise sensitivity and specificity to assess the 453 model's power to correctly find the true segmented areas and discard the unsegmented areas. F1 454 concludes these concepts as a single number. For classification (cancer and resectability), we 455 measure the area under the receiver operating characteristic curve (AUROC), accuracy, 456 sensitivity, specificity, and F1 by using the K-fold cross-validation technique (56). In addition, a 457 calibration curve will be used to show how well the probabilistic predictions of a binary 458 classifier are calibrated (57). We perform a simple statistical test to evaluate the prognosis's 459 predicted mean and variance values. For each ground truth prediction in the test dataset, we

460 examine if it comes from the proposed normal distribution or not. The proportion of samples that461 pass the test is defined as a measure of the model's performance.

462 Explainable AI

463 The adaptation of AI models in the clinical setting has been constrained by their "black-box" 464 nature, which makes it challenging for clinicians to comprehend and believe their predictions 465 (58). Herby, we will embed Explainable AI (XAI) approach to increase its use case in the 466 medical field. XAI is one of the branches of artificial intelligence concerned with building 467 models that can offer clear and understandable justifications for their predictions and choices. By 468 using architectures such as U-net, we can incorporate XAI techniques, such as Layer-wise 469 Relevance Propagation (LRP) or Local Interpretable Model-agnostic Explanations (LIME), and 470 we can provide visual explanations of the model's predictions. Also, by segmenting the 471 cancerous masses and pinpointing their location, medical professionals can better understand the 472 reasons behind the model's decisions and build trust in its predictions (58-60).

473 **Discussion**

The development of CDSS and CAD tools requires interdisciplinary teamwork (17). PanCanAID is a multipurpose CDSS project addressing the current needs of pancreatic cancer care delivery across multiple phases of the disease. In developing the PanCanAID protocol, we addressed various aspects of team building, data collection and annotation, and model development. The process evolved over months of collaborative sessions with medical and computational experts. Many challenges were faced during protocol design, including the feasibility of data collection and annotation, complex multidisciplinary collaboration, optimization of data storage capacity,

and the development of a state-of-the-art ML model. The protocol development process
addressed these challenges and fostered effective cross-disciplinary collaboration toward a
common goal.

484 CDSSs depend highly on a large, precisely-labeled dataset representing real-world data patterns 485 (14). However, the truly adequate dataset size is unknown without conducting pilot studies (34). 486 ML models of medical imaging may require even large datasets than models of tabular data due 487 to the complexities of imaging data. The lack of publicly available cases on The Cancer Imaging 488 Archive (TCIA) highlights the challenge of acquiring pancreatic cancer image data (**Table 3**). 489 We constructed a multi-institutional team and designed it to collect sufficient cases for our 490 models. Our initial aim is to gather 500 cases and 500 controls, but this number may be extended 491 to reach the desired model performance: an AUC of 0.85 for diagnosis and 0.80 for cancer

492 prognosis.

493 The data collection task for pancreatic cancer is more difficult for three reasons. First, a 494 pancreatic cancer diagnosis is a relatively rare event (2). Second, the life span of patients is short, 495 and many cases pass away within the first months, which makes patient identification even 496 harder (1, 61). The third and most important reason is the winding journey of pancreatic cancer 497 patients during diagnosis and management. Multiple medical centers and specialties manage 498 pancreatic cancer, and the data is stored in various sources (Fig 5). The collection of this data 499 needs rigorous amounts of time and a substantial amount of effort (17). We used an ambispective 500 design to collect more accessible cases retrospectively and precise data prospectively. However, 501 finding pathologically confirmed patients with survival outcomes can be unattainable in many 502 cases. We aim to collect the survival of patients, which is needed for some tasks, by calling 503 patients diagnosed in the last year or included prospectively.

504 Fig 5. Dissemination, storage, patient data sources, and the journey of patients with

505 pancreas cancer.

506 The next issue is the time and effort needed to label the data. In our case, tumor characteristics, 507 pancreas segmentation, tumor segmentation, and resectability assessment were warranted. We 508 assembled a team of junior radiologists with six years of experience who will handle 509 segmentation. An active learning model will also be developed using publicly available data for 510 pancreas organ segmentation and less than 100 local cases. Two senior radiologists who are 511 experts in the field will validate and confirm the labeled data. The interobserver variability will 512 be reported to show the use case of CADs. 513 In addition, we sought to collect other data, such as EUS images and clinical data (symptoms, 514 past medical history, and demographics). We will use the collected data to develop a cross-515 modality platform, which is the future direction of PanCanAID. This data bank can overcome the 516 current bottleneck in the model development of pancreatic cancers. 517 Our project involves a comprehensive benchmarking of previous models and the development of 518 new algorithms. However, several challenges make our task more complex than a typical 519 classification/segmentation task. Firstly, labeling all CT scans, particularly those with narrow 520 imaging cuts, is impractical due to the high cost of segmentation labeling. To overcome this, we 521 have adopted an active learning approach where radiologists interact with our team to validate 522 and correct segmentation labels. This results in higher quality annotations and improved sample 523 efficiency. Secondly, the complex structure of abdominal images, especially the irregular shape 524 of the pancreas, can benefit from large-scale external data with extensive labeling. We aim to 525 deploy a domain adaptation framework to transfer the knowledge learned from the large-scale 526 external data into our dataset. Thirdly, we have designed a batch-effect removal protocol to

527 eliminate batch effects in our multi-source data, which we will extend using other domain 528 generalization techniques. Finally, we aim to build our model with unlabeled data, using semi-529 supervised learning as a key component of our framework. 530 Although we tried to overcome several challenges during the protocol design process, several 531 unknown factors could still affect our future work. The presence of all three needed data 532 modalities (CT scans, pathology reports, and survival data) may be unachievable in many 533 pancreatic cancer cases. In addition, the quality of CT scan images, especially in the arterial phase. may be insufficient. Developing a generalizable model will need rigorous effort for batch 534 535 effect removal. In addition, the segmentation and labeling of data require a vast amount of time 536 from radiologists, which may be exhausting. We hope to overcome upcoming challenges through 537 interdisciplinary teamwork.

538 Conclusion

539 PanCanAID is a large-scale AI project developing CADs and CDSSs using pancreatic cancer CT 540 scan images. In hopes of improving pancreatic cancer prognosis, it will tackle the current 541 bottleneck of model development and data shortage. We plan to collect good quality, sufficient 542 amounts, and precisely labeled data banks by creating a team of experts from various institutions. 543 Besides, in our model development, we utilize and expand different concepts according to the 544 challenges we have in our task, including active learning, semi-supervised learning, and domain 545 adaptation and generalization. Experts in medical and computational fields were involved in 546 protocol development, striving to describe the problem from all aspects. The protocol design 547 lasted for months, but it fostered the replicability of the method and cross-disciplinary teamwork.

548 Acknowledgment

- 549 The authors want to thank the National Elite Foundation, Research Institute of Gastroenterology
- and Liver Diseases (Shahid Beheshti University of Medical Sciences), Data Science and
- 551 Machine Learning (DML) Lab (Sharif University of Technology), Advanced Diagnostic and
- 552 Interventional Radiology Research Center (Tehran University of Medical Sciences),
- 553 Gastroenterology and Liver Diseases Research Center (Iran University of Medical Sciences),
- 554 Gastrointestinal and Liver Diseases Research Center (Guilan University of Medical Sciences),
- and Medical Imaging Research Center (Shiraz University of Medical Sciences) for providing
- 556 resources and support.

557 **References**

Khalaf N, El-Serag HB, Abrams HR, Thrift AP. Burden 558 1. of Pancreatic Cancer: From Epidemiology to Practice. 559 Clin Gastroenterol Hepatol. 2021;19(5):876-84. DOI: 560 561 10.1016/j.cgh.2020.02.054. Siegel RL, Miller KD, Jemal A. Cancer statistics, 562 2. 563 2019. CA Cancer J Clin. 2019;69(1):7-34. DOI: 564 10.3322/caac.21551. Aier I, Semwal R, Sharma A, Varadwaj PK. A 565 3. 566 systematic assessment of statistics, risk factors, and underlying features involved in pancreatic cancer. 567 568 Cancer Epidemiol. 2019;58:104-10. DOI: 10.1016/j.canep.2018.12.001. 569 570 Egawa S, Toma H, Ohigashi H, Okusaka T, Nakao A, 4. 571 Hatori T, et al. Japan Pancreatic Cancer Registry; 30th 572 year anniversary: Japan Pancreas Society. Pancreas. 2012;41(7):985-92. DOI: 10.1097/MPA.0b013e318258055c. 573 574 Kato S, Honda K. Use of Biomarkers and Imaging for 5. 575 Early Detection of Pancreatic Cancer. Cancers (Basel). 2020;12(7). DOI: 10.3390/cancers12071965. 576 577 Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain 6. A, Behrman SW, et al. Pancreatic Adenocarcinoma, 578 579 Version 2.2017, NCCN Clinical Practice Guidelines in

580 Oncology. J Natl Compr Canc Netw. 2017;15(8):1028-61. 581 DOI: 10.6004/jnccn.2017.0131. Edge SB, Compton CC. The American Joint Committee 582 7. on Cancer: the 7th Edition of the AJCC Cancer Staging 583 584 Manual and the Future of TNM. Annals of Surgical Oncology. 2010;17(6):1471-4. DOI: 10.1245/s10434-010-585 586 0985-4. 587 8. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human 588 pancreatic cancers revealed by global genomic analyses. 589 590 Science. 2008;321(5897):1801-6. DOI: 10.1126/science.1164368. 591 592 Yoshida T, Yamashita Y, Kitano M. Endoscopic 9. Ultrasound for Early Diagnosis of Pancreatic Cancer. 593 Diagnostics (Basel). 2019;9(3). DOI: 594 10.3390/diagnostics9030081. 595 596 10. McGuigan A, Kelly P, Turkington RC, Jones C, 597 Coleman HG, McCain RS. Pancreatic cancer: A review of 598 clinical diagnosis, epidemiology, treatment and 599 outcomes. World J Gastroenterol. 2018;24(43):4846-61. 600 DOI: 10.3748/wjg.v24.i43.4846. 601 11. Zakaria A, Al-Share B, Klapman JB, Dam A. The Role 602 of Endoscopic Ultrasonography in the Diagnosis and 603 Staging of Pancreatic Cancer. Cancers (Basel). 604 2022;14(6). DOI: 10.3390/cancers14061373. 605 12. Maguchi H. The roles of endoscopic ultrasonography 606 in the diagnosis of pancreatic tumors. J Hepatobiliary Pancreat Surg. 2004;11(1):1-3. DOI: 10.1007/s00534-002-607 608 0752-4. 609 13. Gonoi W, Hayashi TY, Okuma H, Akahane M, Nakai Y, 610 Mizuno S, et al. Development of pancreatic cancer is predictable well in advance using contrast-enhanced CT: 611 612 a case-cohort study. European Radiology. 613 2017;27(12):4941-50. DOI: 10.1007/s00330-017-4895-8. 14. Doi K. Computer-aided diagnosis in medical imaging: 614 615 historical review, current status and future potential. Comput Med Imaging Graph. 2007;31(4-5):198-211. DOI: 616

617 10.1016/j.compmedimag.2007.02.002.

618 15. Francis IR. Role of CT and MR in detection and 619 staging of pancreatic adenocarcinoma. Cancer Imaging. 2003;4(1):10-4. DOI: 10.1102/1470-7330.2003.0026. 620 16. Tonozuka R, Itoi T, Nagata N, Kojima H, Sofuni A, 621 Tsuchiya T, et al. Deep learning analysis for the 622 detection of pancreatic cancer on endosonographic 623 624 images: a pilot study. J Hepatobiliary Pancreat Sci. 2021;28(1):95-104. DOI: 10.1002/jhbp.825. 625 626 17. Chu LC, Park S, Kawamoto S, Wang Y, Zhou Y, Shen W, 627 et al. Application of Deep Learning to Pancreatic Cancer Detection: Lessons Learned From Our Initial 628 629 Experience. J Am Coll Radiol. 2019;16(9 Pt B):1338-42. DOI: 10.1016/j.jacr.2019.05.034. 630 18. Aggarwal R, Sounderajah V, Martin G, Ting DSW, 631 632 Karthikesalingam A, King D, et al. Diagnostic accuracy of deep learning in medical imaging: a systematic 633 634 review and meta-analysis. NPJ Digit Med. 2021;4(1):65. 635 DOI: 10.1038/s41746-021-00438-z. 636 19. Granata V, Fusco R, Setola SV, Castelguidone ELD, 637 Camera L, Tafuto S, et al. The multidisciplinary team 638 for gastroenteropancreatic neuroendocrine tumours: the radiologist's challenge. Radiol Oncol. 2019;53(4):373-639 640 87. DOI: 10.2478/raon-2019-0040. 20. Janssen BV, Verhoef S, Wesdorp NJ, Huiskens J, de 641 Boer OJ, Marquering H, et al. Imaging-based Machine-642 643 learning Models to Predict Clinical Outcomes and 644 Identify Biomarkers in Pancreatic Cancer: A Scoping Review. Ann Surg. 2022;275(3):560-7. DOI: 645 10.1097/sla.000000000005349. 646 21. Jan Z, El Assadi F, Abd-Alrazag A, Jithesh PV. 647 Artificial Intelligence for the Prediction and Early 648 Diagnosis of Pancreatic Cancer: Scoping Review. J Med 649 Internet Res. 2023;25:e44248. DOI: 10.2196/44248. 650 651 22. Hayashi H, Uemura N, Matsumura K, Zhao L, Sato H, 652 Shiraishi Y, et al. Recent advances in artificial 653 intelligence for pancreatic ductal adenocarcinoma. 654 World J Gastroenterol. 2021;27(43):7480-96. DOI: 10.3748/wjg.v27.i43.7480. 655 656 23. Si K, Xue Y, Yu X, Zhu X, Li Q, Gong W, et al. 657 Fully end-to-end deep-learning-based diagnosis of

658 pancreatic tumors. Theranostics. 2021;11(4):1982-90. DOI: 10.7150/thno.52508. 659 24. Liu KL, Wu T, Chen PT, Tsai YM, Roth H, Wu MS, et 660 al. Deep learning to distinguish pancreatic cancer 661 662 tissue from non-cancerous pancreatic tissue: a retrospective study with cross-racial external 663 validation. Lancet Digit Health. 2020;2(6):e303-e13. 664 DOI: 10.1016/s2589-7500(20)30078-9. 665 666 25. Kambakamba P, Mannil M, Herrera PE, Müller PC, Kuemmerli C, Linecker M, et al. The potential of 667 machine learning to predict postoperative pancreatic 668 669 fistula based on preoperative, non-contrast-enhanced 670 CT: A proof-of-principle study. Surgery. 671 2020;167(2):448-54. DOI: 10.1016/j.surg.2019.09.019. 26. Mu W, Liu C, Gao F, Qi Y, Lu H, Liu Z, et al. 672 673 Prediction of clinically relevant Pancreatico-enteric 674 Anastomotic Fistulas after Pancreatoduodenectomy using 675 deep learning of Preoperative Computed Tomography. Theranostics. 2020;10(21):9779-88. DOI: 676 10.7150/thno.49671. 677 678 27. Watson MD, Baimas-George MR, Murphy KJ, Pickens RC, 679 Iannitti DA, Martinie JB, et al. Pure and Hybrid Deep Learning Models can Predict Pathologic Tumor Response 680 to Neoadjuvant Therapy in Pancreatic Adenocarcinoma: A 681 682 Pilot Study. Am Surg. 2021;87(12):1901-9. DOI: 10.1177/0003134820982557. 683 684 28. Zhang Y, Lobo-Mueller EM, Karanicolas P, Gallinger S, Haider MA, Khalvati F. CNN-based survival model for 685 686 pancreatic ductal adenocarcinoma in medical imaging. BMC Med Imaging. 2020;20(1):11. DOI: 10.1186/s12880-687 020-0418-1. 688 29. Kaissis GA, Ziegelmayer S, Lohöfer FK, Harder FN, 689 690 Jungmann F, Sasse D, et al. Image-Based Molecular 691 Phenotyping of Pancreatic Ductal Adenocarcinoma. J Clin Med. 2020;9(3). DOI: 10.3390/jcm9030724. 692 693 30. Ma H, Liu ZX, Zhang JJ, Wu FT, Xu CF, Shen Z, et 694 al. Construction of a convolutional neural network 695 classifier developed by computed tomography images for pancreatic cancer diagnosis. World J Gastroenterol. 696 697 2020;26(34):5156-68. DOI: 10.3748/wjq.v26.i34.5156.

31. Sounderajah V, Ashrafian H, Golub RM, Shetty S, De 698 Fauw J, Hooft L, et al. Developing a reporting 699 quideline for artificial intelligence-centred 700 701 diagnostic test accuracy studies: the STARD-AI 702 protocol. BMJ Open. 2021;11(6):e047709. DOI: 10.1136/bmjopen-2020-047709. 703 32. Mongan J, Moy L, Kahn CE. Checklist for Artificial 704 705 Intelligence in Medical Imaging (CLAIM): A Guide for Authors and Reviewers. Radiology: Artificial 706 707 Intelligence. 2020;2(2):e200029. DOI: 10.1148/ryai.2020200029. 708 709 33. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015: an updated 710 list of essential items for reporting diagnostic 711 712 accuracy studies. Bmj. 2015;351:h5527. DOI: 713 10.1136/bmj.h5527. 714 34. Balki I, Amirabadi A, Levman J, Martel AL, Emersic 715 Z, Meden B, et al. Sample-Size Determination 716 Methodologies for Machine Learning in Medical Imaging 717 Research: A Systematic Review. Can Assoc Radiol J. 718 2019;70(4):344-53. DOI: 10.1016/j.carj.2019.06.002. 719 35. Figueroa RL, Zeng-Treitler Q, Kandula S, Ngo LH. 720 Predicting sample size required for classification 721 performance. BMC Medical Informatics and Decision 722 Making. 2012;12(1):8. DOI: 10.1186/1472-6947-12-8. 723 36. Ma J, Zhang Y, Gu S, Zhu C, Ge C, Zhang Y, et al. 724 AbdomenCT-1K: Is Abdominal Organ Segmentation a Solved Problem? IEEE Transactions on Pattern Analysis and 725 Machine Intelligence. 2022;44(10):6695-714. DOI: 726 10.1109/TPAMI.2021.3100536. 727 728 37. Luo X, Liao W, Xiao J, Chen J, Song T, Zhang X, et 729 al. WORD: A large scale dataset, benchmark and clinical applicable study for abdominal organ segmentation from 730 731 CT image. Medical Image Analysis. 2022;82:102642. DOI: 732 https://doi.org/10.1016/j.media.2022.102642. 733 38. Dao BT, Nguyen TV, Pham HH, Nguyen HQ. Phase 734 recognition in contrast-enhanced CT scans based on deep learning and random sampling. Med Phys. 735

736 2022;49(7):4518-28. DOI: 10.1002/mp.15551.

737 39. National Cancer Institute Clinical Proteomic Tumor 738 Analysis Consortium (CPTAC) The Clinical Proteomic Tumor Analysis Consortium Pancreatic Ductal 739 Adenocarcinoma Collection (CPTAC-PDA) (Version 13) 740 [Data set]. In: The Cancer Imaging Archive, editor. 741 742 2018. 743 40. Clark K, Vendt B, Smith K, Freymann J, Kirby J, Koppel P, et al. The Cancer Imaging Archive (TCIA): 744 745 Maintaining and Operating a Public Information 746 Repository. Journal of Digital Imaging. 2013;26(6):1045-57. DOI: 10.1007/s10278-013-9622-7. 747 41. Roth HR, Lu L, Farag A, Shin H-C, Liu J, Turkbey 748 749 EB, et al., editors. DeepOrgan: Multi-level Deep 750 Convolutional Networks for Automated Pancreas 751 Segmentation. Medical Image Computing and Computer-Assisted Intervention -- MICCAI 2015; 2015 2015//; 752 753 Cham: Springer International Publishing. 754 42. Roth HR, Farag A, Turkbey EB, Lu L, Liu J, Summers 755 RM. Data From Pancreas-CT. In: Archive TCI, editor. 756 2016. 757 43. Hong J, Reyngold M, Crane C, Cuaron J, Hajj C, Mann J, et al. Breath-hold CT and cone-beam CT images with 758 759 expert manual organ-at-risk segmentations from radiation treatments of locally advanced pancreatic 760 cancer [Data set]. In: Archive TCI, editor. 2021. 761 44. Han X, Hong J, Reyngold M, Crane C, Cuaron J, Hajj 762 763 C, et al. Deep-learning-based image registration and 764 automatic segmentation of organs-at-risk in cone-beam CT scans from high-dose radiation treatment of 765 pancreatic cancer. Medical Physics. 2021;48(6):3084-95. 766 767 DOI: https://doi.org/10.1002/mp.14906. 45. Pieper S, Halle M, Kikinis R, editors. 3D Slicer. 768 769 2004 2nd IEEE international symposium on biomedical 770 imaging: nano to macro (IEEE Cat No 04EX821); 2004: 771 IEEE. 772 46. Herrick R, Horton W, Olsen T, McKay M, Archie KA, Marcus DS. XNAT Central: Open sourcing imaging research 773 774 data. NeuroImage. 2016;124:1093-6. 775 47. Settles B. Active learning literature survey. 2009.

48. Bangert P, Moon H, Woo JO, Didari S, Hao H. Active 776 777 learning performance in labeling radiology images is 90% effective. Frontiers in radiology. 2021;1:748968. 778 779 49. Murakami Y, Satoi S, Sho M, Motoi F, Matsumoto I, 780 Kawai M, et al. National comprehensive cancer network 781 resectability status for pancreatic carcinoma predicts 782 overall survival. World journal of surgery. 783 2015;39:2306-14. 50. Van Laethem J-L, Verslype C, Iovanna J, Michl P, 784 Conroy T, Louvet C, et al. New strategies and designs 785 786 in pancreatic cancer research: consensus guidelines 787 report from a European expert panel. Annals of 788 oncology. 2012;23(3):570-6. 789 51. Balakrishnan G, Zhao A, Sabuncu MR, Guttag J, Dalca AV. VoxelMorph: a learning framework for deformable 790 medical image registration. IEEE transactions on 791 792 medical imaging. 2019;38(8):1788-800. 52. Sarafraz G, Behnamnia A, Hosseinzadeh M, Balapour 793 A, Meghrazi A, Rabiee HR. Domain Adaptation and 794 795 Generalization on Functional Medical Images: A 796 Systematic Survey. arXiv preprint arXiv:221203176. 797 2022. 798 53. Guan H, Liu M. Domain adaptation for medical image 799 analysis: a survey. IEEE Transactions on Biomedical 800 Engineering. 2021;69(3):1173-85. 801 54. Roels J, Hennies J, Saeys Y, Philips W, Kreshuk A, 802 editors. Domain adaptive segmentation in volume 803 electron microscopy imaging. 2019 IEEE 16th 804 International Symposium on Biomedical Imaging (ISBI 2019); 2019: IEEE. 805 806 55. Vaswani A, Shazeer N, Parmar N, Uszkoreit J, Jones L, Gomez AN, et al. Attention is all you need. Advances 807 in neural information processing systems. 2017;30. 808 809 56. Hicks SA, Strümke I, Thambawita V, Hammou M, 810 Riegler MA, Halvorsen P, et al. On evaluation metrics for medical applications of artificial intelligence. 811 Scientific Reports. 2022;12(1):5979. DOI: 812 10.1038/s41598-022-09954-8. 813 57. Niculescu-Mizil A, Caruana R, editors. Predicting 814 815 good probabilities with supervised learning.

```
816
    Proceedings of the 22nd international conference on
817
    Machine learning; 2005.
    58. Chaddad A, Lu Q, Li J, Katib Y, Kateb R, Tanougast
818
    C, et al. Explainable, domain-adaptive, and federated
819
820
    artificial intelligence in medicine. IEEE/CAA Journal
    of Automatica Sinica. 2023;10(4):859-76.
821
    59. Karar ME, El-Fishawy N, Radad M. Automated
822
    classification of urine biomarkers to diagnose
823
    pancreatic cancer using 1-D convolutional neural
824
825
    networks. Journal of Biological Engineering.
    2023;17(1):28. DOI: 10.1186/s13036-023-00340-0.
826
827
    60. Montavon G, Binder A, Lapuschkin S, Samek W, Müller
    K-R. Layer-Wise Relevance Propagation: An Overview. In:
828
829
    Samek W, Montavon G, Vedaldi A, Hansen LK, Müller K-R,
830
    editors. Explainable AI: Interpreting, Explaining and
831
    Visualizing Deep Learning. Cham: Springer International
    Publishing; 2019. p. 193-209. DOI: 10.1007/978-3-030-
832
833
    28954-6 10.
834
    61. Moffat GT, Epstein AS, O'Reilly EM. Pancreatic
835
    cancer-A disease in need: Optimizing and integrating
    supportive care. Cancer. 2019;125(22):3927-35. DOI:
836
837
    10.1002/cncr.32423.
838
839
```

```
840
```

841 Supporting Information

- 842 **S1 Table.** The Standards for Reporting Diagnostic Accuracy (STARD 2015)
- 843 **S2 Table.** Checklist for Artificial Intelligence in Medical Imaging (CLAIM)
- 844 **S1 Figure.** STARD 2015 patient flow diagram for PanCanAID
- 845 **S1 Appendix.** The phone interview form for collecting survival and clinical data









